SCHEMBL10950

SCHEMBL10950

FC1CC(c2ccc(Br)cc2)C1F

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 10/20 0.54
MAOB P27338 5/20 0.54
KCNH2 Q12809 2/20 0.54
RCOR1 Q9UKL0 2/20 0.54
KDM1B Q8NB78 1/20 0.54
HTR2C P28335 2/20 0.47
HTR2B P41595 2/20 0.47
MAOA P21397 2/20 0.39
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HRH3 Q9Y5N1 2/20 0.36
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
CYP2A6 P11509 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15606869 0.84 KDM1A (0.60) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL12295868 0.76 KDM1A (0.68) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL883113 0.76 KDM1A (0.68) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL24658830 0.72 KDM1A (0.62) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL12714992 0.72 KDM1A (0.62) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL17403045 0.70 KDM1A (0.60) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL16019172 0.70 KDM1A (1.00) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL1524305 0.70 KDM1A (1.00) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL24658449 0.70 KDM1A (0.60) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL12875752 0.70 KDM1A (0.60) KDM1AMAOBKCNH2RCOR1KDM1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488493-A1 SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES F. Hoffmann-La Roche AG (CH) 2012-08-22 EP disclosed
WO-2011045292-A1 SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2011-04-21 WO disclosed